Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Has Consensus Price Target of $642.33 According to Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Thermo Fisher Scientific, with 18 buy, two strong-buy, three hold and two sell ratings. The average 12-month price target is $642.33, below the stock’s reported $663.46 opening price.
• Recent analyst sentiment has been mixed: Wells Fargo, Citigroup and BMO Capital Markets downgraded the stock, while Piper Sandler initiated coverage with an overweight rating and RBC raised its price target to $580.
• Thermo Fisher exceeded quarterly expectations, reporting $6.03 in EPS versus a $5.71 consensus and $11.99 billion in revenue, up 10.5% year over year. Institutional investors own 89.23% of the shares, while insiders sold $44.1 million worth of stock over the past three months.

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) has received an average recommendation of "Moderate Buy" from the twenty-five analysts that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, eighteen have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $642.33.

Several equities analysts have recently issued reports on the company. Wells Fargo & Company lowered Thermo Fisher Scientific from an "overweight" rating to an "underweight" rating in a research note on Wednesday, September 9th. Citigroup lowered Thermo Fisher Scientific from a "buy" rating to an "underperform" rating in a research report on Wednesday, September 9th. Royal Bank Of Canada boosted their price objective on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a "sector perform" rating in a report on Friday, July 24th. BMO Capital Markets downgraded shares of Thermo Fisher Scientific to a "market perform" rating in a research report on Wednesday, September 9th. Finally, Piper Sandler began coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, September 9th. They set an "overweight" rating on the stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, VP Lisa Britt sold 11,440 shares of the business's stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the sale, the vice president directly owned 14,784 shares of the company's stock, valued at $9,064,366.08. The trade was a 43.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CAO Joseph Holmes sold 420 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the transaction, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Bank OZK acquired a new stake in shares of Thermo Fisher Scientific in the second quarter valued at approximately $1,096,000. Ausdal Financial Partners Inc. bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $456,000. BlackRock Inc. acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $15,501,867,000. German American Bancorp Inc. acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $4,920,000. Finally, Parallax Volatility Advisers L.P. bought a new stake in Thermo Fisher Scientific in the 2nd quarter valued at $814,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $663.46 on Wednesday. The company has a 50 day moving average price of $631.12 and a 200 day moving average price of $544.23. Thermo Fisher Scientific has a fifty-two week low of $435.27 and a fifty-two week high of $694.33. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The stock has a market capitalization of $245.32 billion, a PE ratio of 35.69, a price-to-earnings-growth ratio of 2.77 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%. The business's quarterly revenue was up 10.5% compared to the same quarter last year. During the same period last year, the company earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts forecast that Thermo Fisher Scientific will post 25.13 EPS for the current year.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Improving end-market demand: A Lindsell Train investor letter highlighted a rebound in biotech and pharmaceutical activity that is supporting Thermo Fisher’s organic growth, particularly across bioproduction and related services. Biotech and Pharma Rebound Strengthen Thermo’s Organic Growth
• Positive Sentiment: Upward earnings revision: Erste Group raised its FY2027 EPS forecast for TMO to $27.51 from $27.44, reinforcing expectations for continued earnings growth above the current-year consensus estimate of $25.13. Thermo Fisher analyst estimate update
• Positive Sentiment: Buy-rating upgrade: Zacks upgraded Thermo Fisher to Rank #2, or “Buy,” citing improving earnings prospects. The upgrade can support investor confidence ahead of the company’s results. Thermo Fisher rating upgrade to Buy
• Positive Sentiment: Positive Q3 setup: Analysts expect revenue and EPS growth when Thermo Fisher reports third-quarter results, supported by bioproduction demand, product innovation and strength in clinical research. Thermo Fisher Q3 earnings preview
• Neutral Sentiment: Broader drug-development role: Thermo Fisher is expanding its involvement across clinical trials, drug manufacturing and evidence generation, including a Phase 2 multiple sclerosis program for Quantum BioPharma. The initiatives strengthen its long-term positioning but are not expected to immediately change earnings. Thermo Fisher expanded drug lifecycle role
• Negative Sentiment: Valuation remains a consideration: After a substantial multiyear advance, an analysis suggested TMO is trading near fair value based on expected cash generation. That could make additional gains increasingly dependent on earnings beats or stronger guidance. Thermo Fisher trades near fair value

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company's portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.